Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of adalimumab in children with moderate to severe ulcerative colitis
MOH_2017-09-25_000433Phase 3Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Mar 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of adalimumab in autoimmune colitis (5 arms), sponsored by AbbVie Inc. Primary endpoints: Efficacy of adalimumab and Safety of adalimumab. Started Mar 2014; status: active, not recruiting.
02
Drugs
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on MOH_2017-09-25_000433.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-09-25_000433.